Building a Broad Pipeline of

Leronlimab for HIV Treatment

Our lead product, leronlimab (PRO 140), is a subcutaneous injection for HIV that prevents healthy cells from viral entry.

Read More on Leronlimab

Leronlimab for Oncology

Recent research demonstrates the potential importance of the CCR5 receptor as a therapeutic target in oncology.

Read More on CCR5

Get In Touch

For more information on leronlimab, our science, or our new developments, please reach out to us using the link provided.

Ask a Question